Brain Cancer Information

Cell Phones Do Not Increase Risk of Developing Meningioma (9/29/2008)
Researchers from Finland, Denmark, the United Kingdom, Sweden, and Norway have reported that long-term data do not indicate an association between the use of cell phones and an increased risk of meningioma. The details of this study appeared in an early online publication in the International Journal of Epidemiology on August 2, 2008.

Intravenous Rituxan® Effective in Primary Central Nervous System Lymphomas (9/16/2008)
Researchers affiliated with the NCI-sponsored New Approaches to Brain Tumor Therapy (NABTT) consortium have reported that intravenous Rituxan® (rituximab) may be effective in the treatment of primary central nervous system lymphoma (PCNSL). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology in May, 2008.

CDX-110 Vaccine May Improve Survival in Brain Cancer (6/5/2008)
Researchers affiliated with the ACTIVATE and ACT II trials have reported that the investigative vaccine CDX-110 has demonstrated impressive survival results when compared with historical controls for patients with glioblastoma multiforme (GBM). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

Avastin® Improves Survival in Recurrent Brain Cancer (6/4/2008)
Researchers from the University of California at Los Angeles have reported that patients with recurrent glioblastoma who were treated with Avastin® (bevacizumab) alone experienced a slight survival advantage compared with patients treated with Avastin plus Camptosar® (irinotecan). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.

Cediranib Prolongs Survival in Recurrent Glioblastoma (5/29/2008)
Researchers from the Massachusetts General Hospital, the National Cancer Institute, and the Dana Farber Cancer Center have reported that cediranib (AZD2171) appears to prolong survival among patients with recurrent glioblastoma multiforme (GBM). These results were at the American Association for Cancer Research (AACR) 2008 annual meeting April 12-16 in San Diego.